Company research
Crinetics Pharmaceuticals, Inc.
CIK 1658247Updated Sep 26, 2026
Securities
Historical securities (1)
CRNX · NASDAQ · equity · closed Aug 31, 2026CRNX price & chart
Historical security
This listing closed Aug 31, 2026. Live provider charts are shown only for current listings.
About the company
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
In the news
Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders ↗
Are CRNX, VEEE, ESI Obtaining Fair Deals for their Shareholders? ↗
Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,126,257,000Source | 1,434,592,000Source | 635,353,000Source | 352,176,000Source |
| Property, Plant and Equipment, NetUSD | 14,296,000Source | 12,068,000Source | 10,881,000Source | 3,500,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 101,536,000Source | 264,545,000Source | 54,897,000Source | 32,672,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 592,000Source | — | — | — |
| Inventory, NetUSD | 2,022,000Source | — | — | — |
| Assets, CurrentUSD | 1,048,342,000Source | 1,375,388,000Source | 574,153,000Source | 345,184,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 17,839,000Source | 20,819,000Source | 15,598,000Source | 10,759,000Source |
| Operating Lease, Right-of-Use AssetUSD | 40,492,000Source | 43,507,000Source | 46,549,000Source | 1,486,000Source |
| Other Assets, NoncurrentUSD | — | 2,829,000Source | 2,000,000Source | 37,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 134,174,000Source | 109,787,000Source | 96,247,000Source | 35,848,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | — | — | 253,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -1,417,427,000Source | -952,110,000Source | -653,702,000Source | -439,173,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,865,000Source | 963,000Source | 977,000Source | -3,931,000Source |
| Stockholders' Equity Attributable to ParentUSD | 992,083,000Source | 1,324,805,000Source | 539,106,000Source | 316,328,000Source |
| Liabilities and EquityUSD | 1,126,257,000Source | 1,434,592,000Source | 635,353,000Source | 352,176,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 85,072,000Source | 59,684,000Source | 43,942,000Source | 27,723,000Source |
| Operating Lease, Liability, CurrentUSD | 6,489,000Source | 7,152,000Source | 4,173,000Source | 1,051,000Source |
| Accounts Payable, CurrentUSD | 22,611,000Source | 5,853,000Source | 6,548,000Source | 6,883,000Source |
| Operating Lease, Liability, NoncurrentUSD | 42,052,000Source | 44,570,000Source | 47,555,000Source | 2,024,000Source |
| Other Liabilities, NoncurrentUSD | 3,240,000Source | 829,000Source | — | — |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 1,000,000,000Source | 1,400,000,000Source | 558,600,000Source | 334,400,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | 2,200,000Source |
| Deferred Revenue, NoncurrentUSD | — | 4,704,000Source | 4,750,000Source | 6,101,000Source |
| Deferred Tax Liabilities, NetUSD | — | 9,751,000Source | 9,799,000Source | — |
| Short-term InvestmentsUSD | 926,353,000Source | 1,089,524,000Source | 503,658,000Source | 301,753,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 3,900,000Source | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 91,024,000Source | 69,386,000Source | 40,937,000Source | 28,268,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 592,000Source | — | — | — |
| Increase (Decrease) in InventoriesUSD | 2,022,000Source | — | — | — |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -377,922,000Source | -225,970,000Source | -166,307,000Source | -115,205,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 173,908,000Source | -574,817,000Source | -200,413,000Source | -173,980,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 5,762,000Source | 3,844,000Source | 4,688,000Source | 1,656,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 40,611,000Source | 1,010,435,000Source | 388,944,000Source | 121,963,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | 209,648,000Source | 22,224,000Source | -167,222,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 102,336,000Source | 265,845,000Source | 56,197,000Source | 33,973,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 89,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 91,024,000Source | 69,386,000Source | 40,937,000Source | 28,268,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 1,000,000,000Source | 1,400,000,000Source | 558,600,000Source | 334,400,000Source |
| Debt Securities, Realized Gain (Loss)USD | — | 51,000Source | 0Source | — |
| DepreciationUSD | — | 2,800,000Source | 1,100,000Source | 1,000,000Source |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | 0Source | -470,000Source | -5,198,000Source | -1,010,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -50,000Source | -51,000Source | -6,000Source | — |
| General and Administrative ExpenseUSD | — | 99,737,000Source | 58,094,000Source | 42,394,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 0Source | — | — | — |
| Income Tax Expense (Benefit)USD | 180,000Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | 51,989,000Source | 41,435,000Source | 13,436,000Source | 4,317,000Source |
| Net Income (Loss) Attributable to ParentUSD | -465,317,000Source | -298,408,000Source | -214,529,000Source | -163,918,000Source |
| Nonoperating Income (Expense)USD | 51,632,000Source | 40,916,000Source | 13,277,000Source | 4,974,000Source |
| Operating ExpensesUSD | — | 339,893,000Source | 226,621,000Source | 172,619,000Source |
| Other Nonoperating Income (Expense)USD | -357,000Source | — | — | — |
| Payments of Financing CostsUSD | 0Source | 0Source | 26,000Source | — |
| Proceeds from Issuance of Common StockUSD | 0Source | 970,048,000Source | 369,019,000Source | 117,242,000Source |
| Proceeds from Stock Options ExercisedUSD | — | 40,387,000Source | 19,925,000Source | 4,721,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | 1,039,000Source | 4,013,000Source | 4,737,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 7,696,000Source | 1,039,000Source | — | 0Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 191,331,000Source | — | — | — |
| Operating Income (Loss)USD | -516,769,000Source | -338,854,000Source | -222,608,000Source | -167,882,000Source |
| Other Nonoperating Income (Expense)USD | -357,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | -298,408,000Source | -214,529,000Source | -163,918,000Source |
| Income Tax Expense (Benefit)USD | 180,000Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -465,317,000Source | -298,408,000Source | -214,529,000Source | -163,918,000Source |
| Earnings Per Share, BasicUSD per share | -4.95Source | -3.69Source | -3.69Source | -3.15Source |
| Earnings Per Share, DilutedUSD per share | -4.95Source | -3.69Source | -3.69Source | -3.15Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 94,057,000Source | 80,783,000Source | 58,071,000Source | 51,982,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 94,057,000Source | 80,783,000Source | 58,071,000Source | 51,982,000Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 524,465,000Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | 180,000Source | — | — | — |
| Debt Securities, Realized Gain (Loss)USD | — | 51,000Source | 0Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 3,890,000Source | 2,785,000Source | 1,098,000Source | 983,000Source |
| General and Administrative ExpenseUSD | — | 99,737,000Source | 58,094,000Source | 42,394,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -453,630,000Source | -297,911,000Source | -214,027,000Source | -163,175,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 0Source | — | — | — |
| Investment Income, InterestUSD | 51,989,000Source | 41,435,000Source | 13,436,000Source | 4,317,000Source |
| Nonoperating Income (Expense)USD | 51,632,000Source | 40,916,000Source | 13,277,000Source | 4,974,000Source |
| Operating ExpensesUSD | — | 339,893,000Source | 226,621,000Source | 172,619,000Source |
| Research and Development ExpenseUSD | 332,058,000Source | 240,156,000Source | 168,527,000Source | 130,225,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | 1,039,000Source | 4,013,000Source | 4,737,000Source |
Filing attachments
ef20077399_ex99-1.htm · 8-K · 2026-07-06
EX-99.1 3 ef20077399_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Vertex to Acquire Crinetics Pharmaceuticals - Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor…
Read attachment ↗d22132dex991.htm · 8-K · 2026-01-07
EX-99.1 4 d22132dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock SAN DIEGO - January 5, 2026 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other condit…
Read attachment ↗d22132dex992.htm · 8-K · 2026-01-07
EX-99.2 5 d22132dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock SAN DIEGO - January 6, 2026 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 7,620,000 shares …
Read attachment ↗d86003dex991.htm · 8-K · 2026-01-05
EX-99.1 2 d86003dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) Achieved a 67% …
Read attachment ↗d86003dex992.htm · 8-K · 2026-01-05
EX-99.2 3 d86003dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 J A N U A R Y 2 0 2 6 Corporate Update Forward Looking Statements and Legal Disclaimers Forward Looking Statements: This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Such forward-looking statements include, but a…
Read attachment ↗crnx-ex99_1.htm · 8-K · 2025-06-26
EX-99.1 2 crnx-ex99_1.htm EX-99.1 Research & Development Day June 26, 2025 - New York Exhibit 99.1 This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements, including, but not limited to, statements regarding: the potential for any of our ongoing clinical trials to demonstrate…
Read attachment ↗